AprilBio has secured approximately 430 billion won ($430 million) in funding, positioning itself to test its corporate value through technology exports next year. While the large investment alleviates funding pressures, the key factor influencing future company value will be the success of actual technology transfer agreements. The company plans to accelerate revenue generation by pursuing early technology transfers for three drug candidates and expanding its development areas to include oncology and metabolic diseases.
On November 9, AprilBio held its first research and development briefing, 'R&D Day 2026,' at the Conrad Hotel in Yeouido, Seoul, where it unveiled its growth strategy, 'AprilBio 2.0.'
In July, AprilBio raised 346.8 billion won through a joint investment from TKG Group and IMM. Including existing funds, the company's cash liquidity stood at approximately 430 billion won as of the third quarter of this year. The company plans to allocate about 50.7 billion won for research and development (R&D) next year, aiming to expand new drug development and external technology acquisitions.
The core strategy is to shorten the technology export cycle. AprilBio has signed technology transfer agreements with Lundbeck in 2021 and Abomune in 2024, achieving a cumulative contract value of up to $923 million. The company aims to reduce the previous three-year interval between technology transfers to facilitate quicker follow-up agreements.
To achieve this, AprilBio will change its drug development approach. Previously, the company developed drug candidates sequentially due to cost burdens, but it will now adopt a parallel strategy, developing multiple pipelines simultaneously in autoimmune diseases, metabolic disorders, and oncology. This approach aims to increase the number of candidates available for technology transfer and expedite business outcomes.
Next year, the company has set a goal for early technology transfers for three new pipelines: the dual antibody 'APB-I-005' for treating inflammatory bowel disease, the dual-target siRNA 'APB-O-001' for treating dyslipidemia, and the antibody-drug conjugate (ADC) 'APB-A-001.'
Among these, APB-I-005 is a dual antibody that simultaneously inhibits TL1A and IL-23p19, which are involved in inflammatory responses. Animal studies have confirmed its effectiveness in reducing inflammation and tissue damage, and the company plans to pursue technology transfer ahead of its clinical trial application (IND) in the first quarter of 2028. The other two candidates are also under development with the goal of early technology transfer to global pharmaceutical companies during the preclinical stage.
The foundation for expanding technology exports is the next-generation platform 'REMAP.' This advanced technology enhances the existing SAFA platform, allowing a single antibody to target multiple targets simultaneously. The company plans to expand this to dual antibodies, ADCs, and AOCs to increase its technology transferable assets.
AprilBio will also expand its efforts to introduce promising external drug candidates and engage in joint research. The strategy is to secure external assets in preclinical and clinical stages to accelerate commercialization, rather than relying solely on in-house development. TKG Group will focus on enhancing research infrastructure, while IMM Investment plans to support technology transfers using its global pharmaceutical network.
However, since the three new pipelines are still in the preclinical stage, it remains to be seen whether the technology transfer goals will lead to actual contracts. The key to evaluating the company's future value will be whether the funds secured through large-scale investments translate into successful technology exports beyond just research and development outcomes.
Cha Sang-hoon, CEO of AprilBio, emphasized, "Having cash reserves alone does not automatically increase the company's value. What matters is how we utilize this funding to quickly achieve results."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.